Director Kira Sheinerman Discloses 51.56% Control Stake in Niki BioSolutions Following Merger

summarizeSummary

Director Kira Sheinerman reports a 51.56% stake in Niki BioSolutions, acquired via the DiamiR Biosciences merger. The accompanying Stockholders Agreement grants her board nomination rights and veto power over key decisions, cementing her control.

check_boxKey Events · Ownership and Investor Activity · NIKI

• Control Stake Acquired via Merger

  Kira Sheinerman received 1,515,293 shares (51.56% of outstanding) as non-cash merger consideration for her DiamiR Biosciences shares, giving her majority voting control.

• Governance Rights Secured

  A Stockholders Agreement grants Sheinerman the right to designate two board nominees while owning ≥36% of shares, and one nominee at ≥25%. She also holds consent rights over significant corporate actions while her stake exceeds 25%.

• Merger Consummated, Company Renamed

  The merger closed July 20, 2026, with Aptorum Group Limited domesticating as a Delaware corporation and renaming to Niki BioSolutions, now trading on Nasdaq under ticker NIKI.

• Lock-Up Restriction

  The Stockholders Agreement restricts transfers of Sheinerman's shares for six months following the effective date, limiting immediate liquidity.

auto_awesomeAnalysis · NIKI · Industrial Applications And Services

Kira Sheinerman, a director of Niki BioSolutions, now controls 51.56% of the company's outstanding shares after receiving them as merger consideration in the DiamiR Biosciences deal. This is not a market purchase — the shares were issued in exchange for her DiamiR stock — but the resulting concentration of voting power and the attached Stockholders Agreement give her significant influence over board composition and major corporate actions. For a micro-cap company with a market cap around $6.8 million, a single insider holding majority voting control reshapes the governance landscape entirely.